For a low‑risk essential thrombocytosis patient (age under 60, platelet count >450 ×10⁹/L, no prior thrombotic or bleeding events), should treatment begin with low‑dose aspirin or hydroxyurea?

Low-Dose Aspirin Alone is the Recommended Initial Treatment for Low-Risk Essential Thrombocythemia

For a low-risk essential thrombocythemia patient (age <60, no prior thrombosis), start with low-dose aspirin (81-100 mg daily) alone—cytoreductive therapy with hydroxyurea is NOT recommended as initial treatment. 1

Risk Stratification Framework

Your patient falls into the low-risk category based on the revised International Prognostic Score of Thrombosis for ET (IPSET-Thrombosis), which defines low-risk as:

• Age ≤60 years
• No prior thrombosis history
• Platelet count >450 × 10⁹/L

This risk stratification is critical because it determines whether cytoreductive therapy is warranted 1.

Evidence-Based Treatment Algorithm

Initial Management: Aspirin Monotherapy

Low-dose aspirin (81-100 mg daily) is the standard of care for low-risk ET patients 1. The NCCN guidelines explicitly state that "cytoreductive therapy is not recommended as initial treatment" for this population 1.

The evidence supporting aspirin comes primarily from extrapolation of the ECLAP study in polycythemia vera patients, though direct randomized trial evidence in ET is lacking 1. Despite this limitation, aspirin remains the consensus recommendation across all major guidelines.

When Hydroxyurea Becomes Appropriate

Cytoreductive therapy with hydroxyurea should only be initiated if the patient develops specific indications during follow-up 1:

• New thrombotic event
• Disease-related major bleeding
• Symptomatic or progressive splenomegaly
• Symptomatic thrombocytosis
• Progressive leukocytosis
• Progressive disease-related symptoms (pruritus, night sweats, fatigue)
• Vasomotor/microvascular disturbances not responsive to aspirin (headaches, erythromelalgia)

The Definitive Trial Evidence

The most recent high-quality randomized trial directly addresses your question. In a 2018 open-label RCT of 382 ET patients aged 40-59 years without high-risk features, hydroxycarbamide plus aspirin showed NO benefit over aspirin alone 2. After median follow-up of 73 months:

• No significant difference in vascular events (HR 0.98; 95% CI 0.42-2.25; P=1.0)
• Incidence of vascular events was low at 0.93 per 100 patient-years
• No differences in overall survival, transformation to myelofibrosis, or leukemic transformation
• No difference in quality of life

This trial conclusively demonstrates that preemptive addition of hydroxyurea to aspirin does not reduce vascular events in low-risk patients 2.

Important Nuances and Caveats

Mutation-Specific Considerations

JAK2-mutated patients: Some retrospective data suggest aspirin may be more effective in low-risk JAK2-mutated ET patients, particularly those with cardiovascular risk factors 1.

CALR-mutated patients: One retrospective analysis found low-dose aspirin did not reduce thrombosis risk but increased bleeding in CALR-mutated ET 1. However, the NCCN panel concluded there is insufficient evidence to withhold aspirin from CALR-mutated patients 1.

Extreme Thrombocytosis Exception

Consider observation alone (without aspirin) in low-risk patients with platelet counts >1,000 × 10⁹/L due to increased bleeding risk from acquired von Willebrand disease 1. Aspirin should be used with caution in this setting 1.

Aspirin Dosing Optimization

Recent evidence suggests twice-daily aspirin (100 mg) may be superior to once-daily dosing in ET patients, as adequate platelet thromboxane A2 inhibition does not persist for 24 hours with once-daily dosing due to high platelet production 1, 3. This is consequent to high platelet production rather than increased turnover 3. While additional safety data would be useful, the twice-daily regimen has a favorable risk/benefit profile and could be implemented in clinical practice 3.

Monitoring Strategy

After initiating aspirin 1:

• Monitor for new thrombosis, acquired von Willebrand disease, or disease-related bleeding
• Assess symptom status every 3-6 months using MPN Symptom Assessment Form
• Evaluate for signs of disease progression
• Manage cardiovascular risk factors aggressively
• Perform bone marrow biopsy only if clinical progression is suspected

Why Not Start Hydroxyurea?

The rationale against empiric hydroxyurea in low-risk ET is compelling:

1. No survival benefit demonstrated in this population 2
2. Hydroxyurea carries risks: myelosuppression, leg ulcers, mucocutaneous toxicity, and potential (though controversial) leukemogenic effects with long-term use 4, 5
3. Low absolute thrombosis risk in properly selected low-risk patients (0.93 per 100 patient-years) 2
4. Quality of life: No improvement with cytoreductive therapy in low-risk patients 2

The European LeukemiaNet and NCCN guidelines both reserve cytoreductive therapy for high-risk disease (age >60 years and/or prior thrombosis) or development of specific complications 4, 1.